Form D · Other
Nalu Bio, Inc.
San Francisco, CA · CIK 0001966319
Offering snapshot reported Mar 3, 2023 · SEC filing
- Reported sold
- $4.81M Offering amount: $17.1M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 30, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 3, 2023 | Initial | $4,807,998 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-474858
Series A-1 Preferred Stock, Series A Preferred Stock, and the Common Stock issuable upon conversion thereof.
Source: Form D, filed Mar 3, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Howard Goodwin | Director |
| Caitlyn Krebs | Director, Executive |
| Randall S. Ussery | Director |
| Phyllis E. Whiteley | Director, Executive |
Issuer details
Industry: Other (See others in industry)
Address:
38 Keyes Avenue, Suite 200
San Francisco, CA, 94129
San Francisco, CA, 94129